In a report released yesterday, Maury Raycroft from Jefferies maintained a Buy rating on Alnylam Pharma (ALNY – Research Report), with a price target of $325.00.
Maury Raycroft’s rating is based on several strategic factors surrounding Alnylam Pharma’s recent developments. The company has successfully secured approval for Amvuttra, a treatment for ATTR-CM, and is maintaining a competitive pricing strategy at $478K per year, which is more than double that of stabilizers. This pricing reflects the drug’s unique value proposition, including its ability to treat both PN and CM forms, target the disease at its source, and offer dosing convenience, all of which differentiate it from existing treatments.
Furthermore, Alnylam is well-prepared for the commercial launch, with a comprehensive setup already in place and revenue guidance set between $1.6 to $1.725 billion for 2025. The company is also expanding its treatment sites and expects significant market growth as more patients are diagnosed and treated. The inclusion of wording related to heart failure in the drug’s labeling could facilitate diagnosis and treatment, adding to its market potential. These factors collectively support the Buy rating, indicating a strong outlook for Alnylam’s stock.
In another report released today, Barclays also maintained a Buy rating on the stock with a $329.00 price target.
Based on the recent corporate insider activity of 71 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ALNY in relation to earlier this year.
Questions or Comments about the article? Write to editor@tipranks.com